Want to see PHBID full AI Analyst Report?
Top Page
Pharmagreen Biotech
(OTC:PHBID)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.86
▼(-14.00% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily constrained by very weak financial performance, including minimal revenue scale, persistent operating and cash-flow losses, and a highly stressed balance sheet with deeply negative equity and material debt. With technical indicators unavailable, there is no data-driven support from price momentum, and valuation signals are limited by a negative P/E and no dividend yield information.
Positive Factors
Reduced Operating Cash Burn
The sharp reduction in operating cash burn is a constructive change in financial performance. Although cash generation remains negative and does not yet support self-funding operations, continued improvement could reduce near-term financing pressure if sustained.
Negative Factors
Minimal and Declining Revenue
The extremely small and declining revenue base indicates limited commercial scale and weak market traction. Such low sales provide little coverage for fixed costs, constrain reinvestment capacity, and make a durable path to operating profitability difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Reduced Operating Cash Burn
The sharp reduction in operating cash burn is a constructive change in financial performance. Although cash generation remains negative and does not yet support self-funding operations, continued improvement could reduce near-term financing pressure if sustained.
Read all positive factors
Pharmagreen Biotech (PHBID) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$117.53K
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth167846.30%
EPS Growth-295.83%
CountryUS
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding345,673
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.25
Price to Sales (P/S)277.91
P/FCF Ratio-28.48
Enterprise Value/Market Cap6.15
Enterprise Value/Revenue302.65
Enterprise Value/Gross Profit-1.81K
Enterprise Value/Ebitda1.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmagreen Biotech Business Overview & Revenue Model
Company Description
Pharmagreen Biotech Inc. is a biotechnology solutions provider primarily engaged in cultivating young plant stock for the medical cannabis and CBD hemp industries. Established in 2007, the company operates from its base in Coquitlam, Canada....
How the Company Makes Money
null...
Pharmagreen Biotech Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Sep 2025 | Sep 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.39K | 3.41K | 3.00K | 0.00 | 0.00 |
| Gross Profit | -400.00 | 1.74K | -6.45K | 0.00 | -435.00K |
| EBITDA | -290.49K | -971.18K | 26.36K | 194.27K | -3.76M |
| Net Income | 406.36K | -1.00M | -569.00K | -875.00K | -4.53M |
Balance Sheet | |||||
| Total Assets | 7.54K | 97.68K | 121.57K | 208.97K | 373.08K |
| Cash, Cash Equivalents and Short-Term Investments | 721.00 | 276.00 | 1.25K | 8.02K | 25.30K |
| Total Debt | 355.59K | 356.24K | 372.84K | 338.59K | 270.20K |
| Total Liabilities | 2.69M | 3.23M | 2.30M | 2.03M | 2.07M |
| Stockholders Equity | -2.63M | -3.09M | -2.13M | -1.78M | -1.65M |
Cash Flow | |||||
| Free Cash Flow | -23.30K | -28.09K | -73.84K | -426.57K | -206.08K |
| Operating Cash Flow | -23.30K | -28.09K | -73.84K | -426.57K | -206.08K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 28.89K | 28.55K | 83.37K | 313.71K | 257.50K |
Pharmagreen Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $4.22M | -0.52 | -131.35% | ― | -50.79% | -180.59% | |
44 Neutral | $3.99M | -0.08 | -144.27% | ― | ― | 93.91% | |
41 Neutral | $117.53K | -0.20 | ― | ― | 167846.30% | -295.83% | |
40 Underperform | $1.43K | ― | 156.01% | ― | -8.57% | -52.17% |
* Healthcare Sector Average
PHBID
Pharmagreen Biotech
0.34
-0.66
-66.00%
ADTX
Aditxt
0.04
-25,628.36
-100.00%
ADXN
Addex Therapeutics
3.85
-4.44
-53.53%
MSPR
MSP Recovery
0.01
-3.28
-99.70%
BJDX
Bluejay Diagnostics
0.91
-4.57
-83.41%
AKAN
Akanda Corp
4.23
-86.45
-95.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.